Results 291 to 300 of about 71,732 (355)

Predicting Long‐Term Depression Progression in Parkinson's Disease: A Machine‐Learning Survival Analysis and Risk Score

open access: yesCNS Neuroscience &Therapeutics, Volume 32, Issue 4, April 2026.
We developed and internally validated a machine learning–based survival model for predicting long‐term progression of dPD. Supported by SHAP analysis, the model identified that depressive symptom severity, cognitive impairment, and autonomic dysfunction were the main key clinical predictors for dPD progression.
Defu Liu   +14 more
wiley   +1 more source

GTP release-selective agonists prolong opioid analgesic efficacy. [PDF]

open access: yesNature
Stahl EL   +6 more
europepmc   +1 more source

Evolution of Drug Development Trends in Multiple Sclerosis: Analysis of Mainland China and Global Landscapes From 2004 to 2024

open access: yesCNS Neuroscience &Therapeutics, Volume 32, Issue 4, April 2026.
This registry‐based analysis of 1183 MS clinical trials (2004–2024) shows sustained global activity and a marked increase in mainland China after 2018, predominantly driven by late‐phase and bioequivalence studies. Trial density varied across regions, and IFNAR, CD20, and S1PR1 were the most frequently investigated targets. ABSTRACT Background Multiple
Chaoyang Chen   +7 more
wiley   +1 more source

Vitamin D as a Regulator of the Biological Clock-Implications for Circadian-Metabolic Dysregulation. [PDF]

open access: yesInt J Mol Sci
Vesković M   +6 more
europepmc   +1 more source

Structural Pharmacology of Bufotenine Derivatives in Activating the 5-HT<sub>1A</sub> Receptor for Therapeutic Potential in Depression and Anxiety. [PDF]

open access: yesResearch (Wash D C)
Li SJ   +16 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy